

Denosumab for the treatment of therapy-induced bone loss in non-metastatic breast cancer

<http://guidance.nice.org.uk/TA/Wave20/73>

Dear Consultees and Commentators,

In 2009 the Department of Health asked NICE to produce guidance for the NHS on the use of denosumab for the treatment of therapy-induced bone loss in non-metastatic breast cancer. This referral was based on the expected specific marketing authorisation for this technology. However, the drug has not received a separate marketing authorisation for this indication. The Department of Health have therefore removed this appraisal from NICE's work programme.

If you have any questions, please contact me.

Kind regards,

Jeremy

Jeremy Powell

Technology Appraisal Project Manager

National Institute for Health and Clinical Excellence

MidCity Place | 71 High Holborn | London WC1V 6NA | United Kingdom

Tel: 44 (0)20 7045 2248 | Fax: 44 (0)20 7061 9830

Web: <http://nice.org.uk>